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ORIGINAL ARTICLE
Genomic copy number alterations in clear cell renal carcinoma:
associations with case characteristics and mechanisms of VHL
gene inactivation
LE Moore1, E Jaeger2, ML Nickerson3, P Brennan4, S De Vries2, R Roy2, J Toro1, H Li5, S Karami1, P Lenz6, D Zaridze7, V Janout8, V Bencko9,
M Navratilova10, N Szeszenia-Dabrowska11, D Mates12, WM Linehan13, M Merino14, J Simko2, R Pfeiffer1, P Boffetta15,16, S Hewitt17,
N Rothman1, W-H Chow1 and FM Waldman2
Array comparative genomic hybridization was used to identify copy number alterations in clear cell renal cell carcinoma (ccRCC)
patient tumors to identify associations with patient/clinical characteristics. Of 763 ccRCC patients, 412 (54%) provided frozen
biopsies. Clones were analyzed for significant copy number differences, adjusting for multiple comparisons and covariates in
multivariate analyses. Frequent alterations included losses on: 3p (92.2%), 14q (46.8%), 8p (38.1%), 4q (35.4%), 9p (32.3%), 9q
(31.8%), 6q (30.8%), 3q (29.4%), 10q (25.7%), 13q (24.5%), 1p (23.5%) and gains on 5q (60.2%), 7q (39.6%), 7p (30.6%), 5p (26.5%),
20q (25.5%), 12q (24.8%), 12p (22.8%). Stage and grade were associated with 1p, 9p, 9q, 13q and 14q loss and 12q gain. Males had
more alterations compared with females, independent of stage and grade. Significant differences in the number/types of
alterations were observed by family cancer history, age at diagnosis and smoking status. Von Hippel–Lindau (VHL) gene inactivation
was associated with 3p loss (PoE-05), and these cases had fewer alterations than wild-type cases. The fragile site flanking the FHIT
locus (3p14.2) represented a unique breakpoint among VHL hypermethylated cases, compared with wild-type cases and those with
sequence changes. This is the first study of its size to investigate copy number alterations among cases with extensive patient,
clinical/risk factor information. Patients characterized by VHL wild-type gene status (vs sequence alterations) and male (vs female)
cases had more copy number alterations regardless of diagnostic stage and grade, which could relate to poor prognosis.
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INTRODUCTION
Renal cancer incidence is increasing1 and Central/Eastern Europe
has the highest rates worldwide.2 Most (B90%) adult renal
cancers are renal cell carcinomas (RCC), most of which are clear
cell RCC (ccRCC).3 ccRCC can be further classified by genetic
features, most notably by the presence/absence of Von Hippel–
Lindau (VHL) gene inactivation, which occurs through three
mechanisms: sequence alteration affecting the transcript or
protein, transcriptional silencing because of promoter CpG
hypermethylation and loss of heterozygosity/copy number of
the 3p25-26 locus.4
The VHL protein is involved in tissue-specific responses to
oxygen concentration delivery.5,6 VHL alteration through sequence
changes and/or promoter hypermethylation, leading to
transcriptional silencing, prevents formation of a protein
complex required for hypoxia-inducible factor (HIF) degradation,
resulting in excess HIF protein and a gene expression pattern
facilitating adaption to oxygen deprivation, delivery and
angiogenesis. VHL inactivation subtypes have been associated
with improved prognosis and a favorable treatment response in
some but not all studies.7–11 In contrast, VHL wild-type cases may
occur through mechanisms independent of VHL inactivation.
Generally, VHL inactivation is considered an early event in ccRCC
but other unidentified alterations may accompany VHL alteration
at diagnosis.
ccRCC subgroups have demonstrated different frequencies and
patterns of VHL inactivation associated with known risk factors,
which include obesity, hypertension, smoking, certain occupa-
tional exposures and a positive family history of kidney cancer.12,13
High-intake of fruits and vegetables may reduce risk.1
In this study we used array comparative genomic hybridization
to evaluate chromosomal alterations among incident ccRCC cases
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enrolled in a large case–control study of renal cancer. Risk factors,
tumor histopathological features and VHL gene inactivation were
evaluated for association with the frequency and type of copy
number alterations observed.14–16
RESULTS
Cases with tumor biopsies (N¼ 412) were more likely to be
residents from the Czech Republic, have a family cancer history and
have a higher education level compared with those without biopsies
(N¼ 348) (Supplementary Table 1). Other factors did not differ.
Fraction of genome altered (FGA)
Males had a higher FGA compared with females (P¼ 0.002)
(Figure 1). Stage and grade at diagnosis were associated with
increasing fraction of the genome lost (FGL), fraction of genome
gained (FGG) and total FGA (Po0.0001). Ever smokers had
elevated FGG (P¼ 0.05) and FGA (P¼ 0.05) compared with never
smokers, but trends with current smoking status were not
observed (P¼ 0.62). Individuals without a first degree relative
with cancer had a higher FGA compared with those who did
(27.9% vs 22.8%; P¼ 0.02). A lower FGA was observed in cases
with VHL promoter hypermethylation (20.8%, P¼ 0.03) and
sequence alteration (25.9%, P¼ 0.11), compared with wild-type
cases (30.5%-referent). FGA was not associated with other factors.
Chromosomal alterations
The exact number and percent of all chromosome p and q arm
gains and losses in all ccRCC cases in this study are shown in
Supplementary Table 2. Chromosome arms altered in greater than
25% of cases, and those of previous interest were included in
multivariate models (Table 1). The strongest association was
observed between 3p loss and VHL gene inactivation (Po0.0001).
3p loss was less frequent among VHL wild-type compared with
inactivated cases (70.2% vs 95.3%, respectively). Therefore, 29.8%
of VHL wild-type and 4.7% of inactivated cases had 3p present. No
other factors with the exception of VHL inactivation were
associated with 3p loss. Stage was strongly associated with 9p,
9q and 13q (Po0.0001), and to a lesser extent 1p, 10q and 14q
losses. Stage was associated with 12p and 20q gains (P¼ 0.001).
Grade was strongly associated with 8p and 14q (P¼o0.0001) and
also 1p, 4q, 6q, 9p, 9q and 13q losses. Gains associated with grade
were observed at 5p, 7p, 7q and 12q.
After adjustment, male cases had more losses of 3q, 9p, 9q, 13q,
14q and gains of 5p, 7q, 12p, 12q, 20q. Most of these alterations
were associated with stage and/or grade. Patients 65 years or
older had more 4q, 9p and 9q losses compared with younger
patients diagnosed before age 50. Individuals that reported a
family cancer history had fewer 7q gains and 8p losses, explaining
the lower FGA observed. In contrast, there were no chromosome
arm alterations associated with smoking status. Interestingly, 5q
gain was frequently observed although it was not associated with
any of the patient/clinical characteristics or risk factors evaluated.
Closer examination revealed that gains occurred distally, specifi-
cally at two regions (that is, 5q34–35 (55–58%), 5q31–32 (52–54%)
and 5q21–23 (34–49%) (Supplementary Figure 1)).
Loci
Differences in copy number alteration prevalence at specific loci
and risk factors were compared using a moderated t-statistic or F
Figure 1. Fraction (%) of the FGL, FGG and FGA among ccRCC case subgroups. P-values between subgroups were as follows: males vs females
(P¼ 0.002), age (o50, vs X50 years, P¼ 0.06), any family history of cancer (P¼ 0.02), stage (Po0.00001), grade (Po0.0001), ever vs never
smoking (P¼ 0.05), VHL wild-type cases vs those with VHL promoter hypermethylation (P¼ 0.03), VHL wild-type cases vs those with VHL
sequence alterations (P¼ 0.17). REF, referent group.
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statistic with pooled variance, controlling the false discovery rate
(FDR). High frequency clonal alterations were sorted initially by
FDR-adjusted P-values. Subsequently, significant loci were re-
analyzed in adjusted models (Table 2). Grade was associated with
loss of large regions on 4q, 9q, 13q, 14q, 18q and gains on 1q, 7p.
Stage was associated with large losses on 9p, 9q, 13q, 14q, 17q,
18q and gains on 3q and 7q. Both stage and grade were
associated with loss of 1p36; 4q11-12,26; 9p21-22; 9q21-21.3;
14q13-14, 21, 24, 31-32; 18p11.2-12, 18q11-12, 21.3-23, tel; and
gains on 3q22-23; 17q24-25; and 20q13. Both stage and grade
were associated with losses on 14q23.2, a region harboring the
HIF1A gene, and 14q13.2 harboring the PHD1–EGLN3 gene. We
examined HIF1A protein expression in tumor tissue microarrays
using immunohistochemistry, in relation to 14q and regional
(clonal) loss across the HIF1A region (14q23). Although univariate
analyses suggested a decrease in expression with 14q and 14q23
loss, neither factor was associated with HIF1A expression after
adjustment for stage and grade. Stage and particularly grade
remained strongly associated with HIF1A expression, independent
of 14q loss (data not shown).
Male cases exhibited losses on 6p22, 6p24–25, large regions of
9q and gains at 1q43-44, 12p12.3, 12q12.4, 24-tel, compared with
females (Table 3). These alterations were also associated with
stage and grade. Among cases reporting a positive family cancer
history, fewer cases demonstrated losses at 4q21-23 (11% vs 24%,
P¼ 0.002) and gains at 20q13.2 (13% vs 26%, P¼ 0.002). Former
and current smokers exhibited more loss at 3q12 (24% vs 40%,
P¼ 0.04) and gain at 16p11.2-13 (22% vs 11%, P¼ 0.003).
Interestingly, a significant positive trend was observed with
current smoking status and gain at 16p11.2-13.2 (P-trend¼ 0.003).
Lastly, copy number alteration of specific clones and VHL
inactivation status were evaluated. The lowest FDR-adjusted
P-values that remained significant in multivariate analyses were
losses observed at clones RP11-245E5 (3p24; Po0.0001) and RP11-
180G14 (3p14.3; Po0.0001). RP11-180G14 (3p14.3) is located just
distal to CTD-2175D15 (3p14.2), a clone harboring the FHIT locus
(Figure 2).
To follow-up upon these observations, the prevalence of all 3p
losses was compared between groups stratified by VHL inactiva-
tion characteristics. Clonal alteration prevalence among wild-type
cases were compared separately to cases demonstrating inacti-
vated through VHL promoter hypermethylation or sequence
alteration. Loss of these 3p clones was significantly greater among
cases with VHL sequence alterations compared with wild-type
cases. Losses were significantly more prevalent at the 3p telomere
(93% vs 59%, Po0.00001), and clone CTB110-J24 (3p25-26;VHL)
(95% vs 62%, Po0.00001) (Region A-Figure 2), and at 3p14.2 (FHIT)
(92% vs 75%, P¼ 0.001) but not at regions proximal to the
centromere. Loss of 3p loci among VHL hypermethylated cases
was similar in prevalence to cases with sequence alterations but
significantly higher compared with wild-type cases at the 3p
telomere (83%, P¼ 0.03) and the VHL locus (91%, P¼ 0.0006)
(Region A-Figure 2), but not significantly different to wild-type
cases at loci centromeric to clone RP11-180G14 (3p14.3; Region
B-Figure 2). Loss among hypermethylated cases was significantly
less prevalent than among cases with sequence alterations at
3p14.2 (84%, P¼ 0.04) and regions proximal to the centromere
(50%, P¼ 0.0002). These findings demonstrate differences in 3p
loci loss between VHL inactivation subgroups, in particular clones
surrounding the fragile FHIT locus. Lastly, VHL wild-type cases were
Table 1. Regression analysis of selected chromosomal arm alterations patient/clinical factors
Chromosome arm Risk factors Odds ratio (95% confidence intervals) P-value
1p Grade: I, II (REF) vs III, IV 2.4 (1.3–4.2) 0.003
Stage: T1 (REF), T2, T3-4 1.6 (0.7–3.4); 3.7 (1.6–8.5) 0.001
3p VHL gene inactivation: no (REF) vs yes 1250 (476–3125) o0.0001
3q BMI: o25 (REF), 25–30, 30þ 2.5 (1.4–4.6); 1.9 (1.0–3.7) 0.01
Sex: female (REF) vs male 2.4 (1.5–4.2) 0.0004
4q Grade: I, II (REF), vs III, IV 2.3 (1.4–3.6) 0.001
Age: o50 (REF), 50–60, 60þ 1.6 (0.8–2.9); 3.0 (1.5–5.7) 0.001
5pþ Grade: I, II (REF), vs III, IV 1.6 (1.2–3.0) 0.02
6q Grade: I, II (REF), vs III, IV 2.1 (1.3–3.3) 0.004
7pþ Grade: I, II (REF), vs III, IV 2.1 (1.3–3.4) 0.003
7qþ Family history cancer: no (REF) vs yes 0.6 (0.4–0.9) 0.02
Grade: I, II (REF), vs III, IV 2.1 (1.3–3.3) 0.004
8p Grade: I, II (REF), vs III, IV 3.0 (1.8–5.0) o0.0001
Family history cancer: no (REF) vs yes 0.6 (0.4–0.9) 0.01
9p Grade: I, II (REF), vs III, IV 2.2 (1.3–3.7) 0.003
Stage T1 (REF), T2, T3-4 3.3 (1.5–7.4); 6.3 (2.6–14.8) o0.0001
Age: o50 (REF), 50–60, 60þ 1.9 (0.9–3.7); 3.1 (1.5–6.3) 0.006
Sex: female (REF) vs male 2.0 (1.2–3.1) 0.007
9q Grade: I, II (REF), vs III, IV 2.5 (1.4–4.2) 0.001
Stage T1 (REF), T2, T3-4 3.9 (1.6–9.2); 7.5 (3.0–18.6) o0.0001
Age: o50 (REF), 50–60, 60þ 1.6 (0.8–3.2); 2.9 (1.4–5.9) 0.007
Sex: female (REF) vs male 2.4 (1.5–4.0) 0.0006
12pþ Stage T1 (REF), T2, T3-4 2.8 (1.2–6.6); 5.0 (2.1–12.2) 0.001
Sex: female (REF) vs male 2.1 (1.3–3.7) 0.005
12qþ Stage T1 (REF), T2, T3-4 1.2 (0.9–5.2); 4.8 (2.0–11.9) 0.001
Grade: I, II (REF), vs III, IV 2.2 (1.8–4.0) 0.01
Sex: female (REF) vs male 2.3 (1.2–4.4) 0.01
13q Stage T1 (REF), T2, T3-4 4.4 (1.3–15.1); 13.3(3.8–46.6) o0.0001
Grade: I, II (REF), vs III, IV 3.2 (1.9–5.6) o0.0001
14q Organic solvents: no (REF) vs yes 1.9 (1.1–3.2) 0.03
Sex: female (REF) vs male 1.9 (1.1–3.1) 0.03
Stage T1 (REF), T2, T3-4 1.5 (0.8–2.9); 3.1 (1.5–6.7) 0.006
Grade: I, II (REF), vs III, IV 4.4 (2.34–8.2) o0.0001
20qþ Stage T1 (REF), T2, T3-4 1.3 (0.7–2.8); 3.1 (1.5–6.5) 0.001
Abbreviations: BMI, body mass index; VHL, Von Hippel–Lindau gene. Adjusted for Center, age, sex, stage, grade and VHL gene inactivation.
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Table 2. Regional clone and copy number alterations and ccRCC tumor stage and grade
Chromosome
arm
Clone with
highest signal
Regions altered Start (Mb) End P-valuea Grade I, II (%)
vs III, IV (%)
ORb 95% CIb P-value
adjb
Grade
1p RP11-60J11
(1p36.2)
1p36 7041.726 7 232 439 0.0041 14/33 2.94 (1.66–5.21) 0.00001
1qþ RP11-104A2
(1q32-41)
1q25, 31-41, 45 206 402.345 2.07Eþ 08 1.58E-05 9/31 4.42 (2.34–8.36) 0.00001
3qþ RP11-219P10 3q22-23 137 606.200 1.38Eþ 10 0.0037 12/25 1.96 (1.07–3.61) 0.03
4p RP11-176I4
(4p15.1)
4p14-16 33 086.961 33 087 410 5.85E-05 14/33 3.10 (1.73–5.57) 0.0001
4q RP11-6K22
(4q 26-27)
4q11-13, 24,26-
31,34,35
120 282.900 1.20Eþ 08 7.79E-06 13/32 3.43 (1.88–6.26) 0.0001
6q RP-2202A14
(6q14)
6q14 79 297.260 79 474 213 0.0034 19/37 2.09 (1.22–3.56) 0.007
7pþ RP11-161C7
(7p22.3)
7p13-14,21-22.3 6215.911 6 396 692 0.0002 2543 2.27 (1.36–3.79) 0.002
7qþ RP11-10D8
(7q22.1)
7q22.1-.3 98 067.790 98 216 726 3.78E-05 28/46 2.17 (1.31–3.60) 0.003
8p RP11-182G2
(8p22)
8p22-23 4457.862 4 614 130 3.33E-06 30/53 2.59 (1.56–4.27) 0.0001
9p RP11-85J5
(9p21.3)
9p21-22 24 524.208 24 524 427 1.97E-05 26/49 2.32 (1.38–3.92) 0.002
9q RP11-106O17
(9q22.3)
9q21-33 94 882.444 94 882 881 8.72E-06 25/47 2.19 (1.30–3.68) 0.003
11q RP11-42L18
(11q22.3-23)
11q22-23 107 422.086 1.08Eþ 08 2.32E-05 8/25 3.81 (1.93–7.53) 0.0001
12qþ RP11-89J2
(12q24.32)
12q13-14, 24.32 124 666.600 1.25Eþ 08 0.0005 17/29 1.81 (1.26–3.68) 0.04
13q RP11-11C5
(13q21.3)
13q12-14.3, 21-tel 72 013.886 72 183 774 2.34E-06 10/41 5.36 (2.94–9.77) 0.00001
14q RP11-26M6
(14q13)
14q12-14, 21.3-
32.2
34 404.822 34 591 592 2.34E-06 34/67 3.18 (1.91–5.28) 0.00001
17qþ RP11-84E24
(17q24-25)
17q24-25, tel 67 512.626 67 693 011 3.78E-05 5/22 4.50 (2.16–9.39) 0.00001
18p CTD-2048F17
(18p12)
18p11.21-11.32,12 8396.160 8 396 803 3.51E-06 14/38 3.24 (1.84–5.69) 0.00001
18q RP11-60P1
(18q21.3)
18q11-12, 21.3-23,
tel
59 072.800 59 251 211 3.44E-06 16/44 3.80 (2.20–6.55) 0.00001
20qþ CTD2238P18
(20q12)
20q12,13 45 712.070 45 864 616 0.0001 17/37 2.28 (1.32–3.94) 0.003
Chromosome
arm
Clone with
highest signal
Regions
altered
Start (Mb) End P-valuea Stage I, II (%)
vs III, IV (%)
ORb 95% CI P-value
adjb
Stage
1p RP11-219F4
(36.2–36.3)
1p36.2-36.3 14 774.025 14 774 291 0.002 17/29 2.16 (1.26–3.72) 0.005
2pþ RP11-57F9 2p23 28 514.930 28 515 223 0.0056 13/23 1.89 (1.06–3.38) 0.03
2qþ CTD-
22500B20
(2q22)
2q22-24.3 158 357.236 158 357 713 0.0034 9/20 2.94 (1.52–5.71) 0.001
3qþ RP11-160A13
(3q23-24)
22-24, 26-29,
tel
144 154.808 144 312 333 0.0015 12/25 1.74 (0.97–3.11) 0.06
4p RP11-126C7
(4p13)
11-12,13 38 087.290 38 242.92 0.0066 12/26 2.24 (1.32–3.41) 0.03
4q RP11-101N17
(4q26)
4q11-12, 26 120 563.175 120 720 926 0.0003 14/29 2.42 (1.35–4.43) 0.003
6p RP11-284E1
(6p12)
6p12, 24-25 53 823.776 53 824 135 0.0003 14/30 2.48 (1.37–4.42) 0.001
7qþ RP11-38P11
(7q32)
7q26.2-.3,
32,34,36.3
129 557.600 129 557 976 0.0018 26/41 1.63 (1.02–2.63) 0.04
9p RP11-125K10
(9p24)
9p21-24, tel 4819.655 4 991 841 8.63E-0.05 28/49 2.17 (1.33–3.53) 0.002
9q RP11-8D10
(9q21.3)
9q12-21.3 82 120.447 82 209 078 8.63E-0.05 28/46 2.28 (1.41–3.70) 0.001
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distinguished by having more gains at clone LLNL-255K9 (20q11-
12) compared with inactivated cases (33% vs 20%, P¼ 0.03)
(Table 3), a clone that was also more prevalent in cases with
higher stage.
Amplifications
High-level amplifications were observed at 154 clones among 24
cases (1–28 amplifications/case). The most frequent amplifications
were located at clones RP11-28l11 (11p15.2-15.4; N¼ 6), RP11-
Table 2 (Continued )
Chromosome
arm
Clone with
highest signal
Regions
altered
Start (Mb) End P-valuea Stage I, II (%)
vs III, IV (%)
ORb 95% CI P-value
adjb
12pþ RP11-78F16
(12p11.2)
12p11.2,12.1-
13.1
31 959.002 32 128 568 0.0005 20/32 2.04 (1.20–3.45) 0.008
12qþ RP11-89E9
(12q23)
12q23.3 97 222.144 97 411 481 0.0005 18/31 2.14 (1.26–3.64) 0.005
13q RP11-8C15
(13q12.1)
13q12.1,12.3-
14.3,21.1-tel
20 985.475 20 993 099 8.63E-0.05 15/38 3.72 (2.11–6.57) o0.00001
14q RP11-206J4
(14q23)
14q13-24, 31-
32, tel
63 996.230 64 080 508 0.0003 38/62 2.36 (1.48–3.75) o0.00001
16p CTD-2032H1 16p13 3232.028 3 296 628 0.0104 14/28 2.01 (1.28–3.33) 0.01
17qþ RP11-86L18 17q12-
25.3,36
153 645.400 153 645 775 0.0003 27/43 1.63 (1.02–2.60) 0.04
18p RP11-106J7
(18p11.21-
.23)
18p11.2-12 3268.728 3 443 000 0.0002 13/35 3.15 (1.81–5.48) o0.00001
18q RP11-12J12
(18q22)
18q11-12, 21-
23, tel
55 424.497 55 607 583 3.14E-0.06 27/43 2.84 (1.68–4.88) o0.00001
20qþ LLNL-255K9 20q13.2 55 338.240 55 352 455 0.0005 15/34 2.24 (1.31–3.82) 0.003
Abbreviations: ccRCC, clear cell renal cell carcinoma; CI, confidence interval; OR, odds Ratio. aP-value adjusted for multiple comparisons. bOR, 95% CI and P-
values from multivariate models(MV) adjusted for age, sex, country stage, grade, smoking status and family history of cancer.
Table 3. Regional clone and copy number alterations and patient/tumor characteristics
Sex Clone with
highest signal
Region
altered
Start (Mb) End P-value
adja
Male (%)/
female (%)
OR
(MV)b,c
95% CIb P-valueb
1qþ RP11-188A4
(1q43-44)
1q43-44 239 316.500 2.39Eþ 08 0.002 17/9 2.56 (1.43–4.55) 0.04
6p RP11-52C20
(6p22)
6p22, 24-25 23 943.950 24 112 567 0.01 22/11 2.22 (1.18–4.17) 0.003
9q RP11-19014
(9q13)
9q13, 21.1-22,
33
70 455.470 70 634 947 0.003 38/21 2.13 (1.30–3.57) 0.001
12pþ RP11-174L5
(12p12.3)
12p12.3 14 735.670 14 736 047 0.001 38/19 2.44 (1.45–4.00) 0.001
12qþ RP11-29G23
(12q12.4)
12q12.4, 24-
tel
43 908.780 43 909 199 0.02 25/14 1.92 (1.11–3.33) 0.004
Family history No (%)/yes (%)
4q RP11-7G22
(4q21.3-22)
4q21-23 84 523.610 84 723 458 0.002 24/11 2.70 (1.45–5.26) 0.002
20qþ RP11-15M15
(20q13.2)
20q13.2 51 109.650 51 266 870 0.003 26/13 2.38 (1.41–4.55) 0.002
Ever smoker Never (%)/ever (%)
16pþ RP11-150K5
(16p11.2)
16p11.2-13.2 29 825.190 29 825 404 0.003 11/22 2.72 (1.42–5.21) 0.003
3q CTD-2014B13
(3q13.2)
3q12-14 100 971.500 1.01Eþ 08 0.03 24/40 1.73 (1.06–2.83) 0.04
Von Hippel–Lindau gene alteration Wild-type (%)/altered (%)
3p RP11-180G14
(3p14.3)
3p14.3 59 538.560 59 538 883 0.02 71/92 4.88 (2.23–10.68) o0.00001
RP11-245E5
(3p24)
3p21-25, tel 22 747.910 22 936 416 1.97E-07 63/95 13.48 (6.01–30.20) o0.00001
20qþ LLNL-255K9
(20q13.2)
20q11-13.2 55 338.240 55 352 455 0.03 33/20 2.08 (1.04–4.17) 0.03
Abbreviations: CI, confidence interval; MV, multivariate model; OR, Odds Ratio. aP-value adjusted for multiple comparisons. bOR, 95% CI and P-values from MV
adjusted for age, sex, country stage, grade, smoking status and family history of cancer. cORs presented for most prevalent comparison group (underlined).
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10M23, RP11-91H14, RP11-121G20 (6p21.1-21.2; N¼ 5) and CTB-
136O14 (12q14; N¼ 3). Two cases (one VHL wild-type with 3p
present; one VHL inactivated with 3p loss) demonstrated 2q/6p co-
amplifications. The 2q overlapping region (B179.4–199.8Mb)
covers B100 genes; the 6p overlapping region (B39.1–45.7Mb)
included the VEGF (vascular endothelial growth factor) gene.
DISCUSSION
Previous studies have utilized copy number profiling to classify
histologically categorized RCC cases into molecularly defined
subtypes (Table 4).17–22 Consistent with previous studies, the most
common alterations were loss of 3p, 14q and gain of 5q.17–22 Two
previous comparative genomic hybridization studies examined
associations between RCC copy number variation with stage and
grade.18,20 One study (51 cases) reported two clusters defined
solely by the alteration subtypes observed.18 In both clusters, 3p
loss and 5q gain were frequently observed, however, one cluster,
defined by losses on 1p, 4, 9, 13q and 14q, had a higher stage and
grade, increased vascular involvement and lower overall survival
that were independent of stage and grade.18 Another study (51
cases) reported a difference in genomic copy number and
expression profiles between cases with/without biallelic VHL
loss.18 A study of 80 cases observed significant associations with
stage and loss of 14q and 18p.20 In the current study, both stage
and grade were associated with losses on 14q harboring HIF1A
(14q23.2) and PHD1-EGLN genes (14q13.2). Recently, genetic and
functional studies reported that HIF1A is a target of 14q loss and
that HIF1A activity is diminished in 14q deleted RCC cases.21 Loss
of these loci being associated with 14q loss was not corroborated
in the current study, perhaps because of differences in type of
study design and laboratory methodologies. In the current study,
loss of specific loci spanning 14q23 was associated with stage and
grade, which is consistent with the poor prognosis reported in 14q
deleted cases.18
This is the first study to evaluate 3p loci loss among large
numbers of cases that were also defined by VHL status. In
multivariate analyses, only VHL gene alteration was associated
with 3p loss. Cases with VHL promoter hypermethylation were
similar to those with sequence alterations at loci distal to the FHIT
locus, and to wild-type cases at loci centromeric to FHIT. This
observation suggests that in hypermethylated cases, the FHIT
breakpoint could be critical in terms of somatic copy number loss
of the chromosome segment distal to 3p14.2. In contrast, the FHIT
fragile site was not a significant breakpoint in VHL wild-type or
cases with sequence alterations. The FHIT region spans the most
common fragile site of the human genome (the FRA3B fragile site)
encompassing the previously observed familial kidney cancer
breakpoint (t(3;8) p14.2;q24) and a viral integration site.23–25
Hemizygous, interstitial or terminal 3p deletions involving the FHIT
gene and reduced protein expression have been observed in over
90% of ccRCC cases, similar to that observed in the current study
(89%).
In addition to heterogeneity across 3p by VHL inactivation
subgroups, we found that wild-type tumors had more alterations
compared with those with VHL inactivation through promoter
hypermethylation; corroborating a previous report that wild-type
cases may be less genetically stable than hypermethylated cases,
and possibly those with sequence alterations.20 The higher
genomic instability among wild-type cases suggests a greater
potential for progression, as copy number alterations have been
associated with tumor stage, grade and worse prognosis.
Analyses of patient characteristics revealed that male cases had
more alterations compared with females. The most prevalent copy
number alterations in males occurred independently of stage and
grade. This could indicate that incident male ccRCC tumors could
be more aggressive compared with female cases, regardless of
stage or grade at diagnosis. Male patients might also benefit from
more aggressive treatment, follow-up and their genetic alterations
could provide clues for targeted therapies. Several target genes on
chromosome 9 include CDKN2A and CDKN2B.19,20 Other risk
factors examined did not explain the sex differences observed.
Additional characteristics associated with tumor heterogeneity
included having a first degree relative with cancer in which fewer
Figure 2. Frequency of copy number loss of 3p clones among ccRCC cases grouped by absence (wild-type) or presence of VHL gene
inactivation (through sequence alteration or promoter hypermethylation). Region A (telomere to RP11-180G14): the frequency of copy
number loss of individual 3p clones differed significantly between VHL wild-type and inactivated cases that occurred through both sequence
alteration (Po0.00001) and promoter hypermethylation (P¼ 0.03–0.001). Region B (from RP11-180G14to RP11-154H23): the frequency of
clonal copy number loss differed significantly between wild-type cases and those with sequence alterations (P¼ 0.003–o0.00001), but was no
longer observed with hypermethylated cases (P¼ 0.08–0.59).
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copy number alterations were observed compared with those
without cancer history. Smoking was associated with higher FGA.
Ever smoking was associated with copy number loss of 3q12-14,
gain of 16p11.2-13.2 for which a significant, positive trend with
current smoking status was found.
As previously reported, 5q gain was highly prevalent and was
not associated with of stage, grade, VHL inactivation suggesting
that these loci may provide clues to the location of additional
genes that are also altered in the early stages of ccRCC
development. Two recent studies that employed SNP arrays19,20
also observed gains at the distal end of 5q. Expression analysis
revealed overexpression of 12 of 22 5q genes in tumor compared
with normal cortex, including: GNB2L1, MGAT1, RUFY1, RNF130,
MAPK9, CANX, CNOT6, SQSTM1, LTC4S, TBC1D9B, HNRPH1, and
FLT4.19 A second study reported focal amplification of 5q35.3
containing the SQSTM1 gene that is overexpressed in other
cancers.20 The weak correlation between 5q gain and 3p loss
across studies suggests that new targets, perhaps functioning
through VHL-HIF independent mechanisms, could be identified
on 5q.
This study included a large series of histologically-confirmed
ccRCC cases with detailed risk factor and patient/clinical informa-
tion. Our two-step analytical approach, entailing FDR adjustment
and subsequent multivariate analyses of significant loci, reduced
possible false-positive reporting. Weaknesses included a low
sample size for interaction analyses and potential selection bias
from exclusion of almost 50% of cases. We also used a relatively
low resolution array compared with some studies. However, the
current study utilized available high-quality information on each
patient and RCC risk factors to an extent not previously evaluated
Table 4. List of published comparative genomic hybridization (CGH) studies of kidney and renal cell carcinoma (RCC)
Manuscript Sporadic
ccRCC
Cases
Other tissues
evalauted
Method Factors evaluated Finding
Wilhelm et al.22 16 13 Papillary,
5 chromophobe,
Array CGH-
329 clones
RCC subtype
segregation
Segregation of kidney tumor histological sub-
types by copy number variation (CNV) differences
6 Oncocytoma,
2 normal kidney
ccRCC 3p , 5qþ , and 6q , 8p ,
9p or 14q
Toma et al.17 22 22 Matched
normal tissue
Affymetrix
10k chip
Survival CNV most frequent at 3p , 5qþ , 14q ,
9 ,7qþ , 6q
qPCR,
immunohistochemistry
(IHC)
Novel microdeletions at Chr1 , Chr 4, Chr6,
Chr8 and Chr 9
Some alterations validated using gene and
immunohistochemical (IHC) protein
expression assays
Arai et al.18 51 NA array CGH
(4361 BACs)
Survival, grade, stage,
vascular Involvement
Promoter methylation
in 9 genes
CNV most frequent at 3p , 5qþ , 7þ
Genetic cluster profiles associated with
survivial, independent of grade, stage
Chen et al.20 80 NA Illumina 317K
SNP array
Stage, grade, telomere
length
CNV most frequent at 3p , 5qþ , 8p12-pter,
6q23.3-27, 14q24.1-qter, 9q32-qter,
Demographics,
smoking,
alcohol, medical Hx
10q22.3-qter, 9p13.3-pter, 4q28.3-qter,
1q25.1-qter, 7q21.13-qter, 8q24.12-qter
Loss of heterozygosity (LOH) 9p, 9q, 14q,
18q associated with grade
LOH 14q, 18p, 21q associated with stage
LOH 2q, 6p, 6q, 9p, 9q, 17p associated
with short telomere length
Beroukhim
et al.19
49, 5
Metastases
36 Tumors/12
VHL patients
Affymetrix
250K StyI
Von Hippel–Lindau
(VHL) disease, VHL
inactivation, grade,
CNV most frequent at 3p , 14q , 5qþ
CNV higher in VHL WT compared with
VHL disease cases
Gene expression
differences
LOH 1p, 3p (VHL), 4q, 6q, 8p, 9p
(CDKN2A, 2B) and 14q
Amplification 1q, 2q, 5q, 7q, 8q (MYC),
12p and 20q
Shuib et al.21
(data com-
bined with
Beroukim
et al.)
22 VHL
wild-type
(WT)
57 VHL patients Affymetrix
250K
VHL disease
(germline)
CNV most frequent at 3p , 14q , 5qþ
7pþ , 8p (TNFRSF10C, DUSP4) associated
with germline VHL clear cell RCC
17p (TP53), 2pþ (HIF2A) associated with
VHL wild-type ccRCC
Moore et al.,
current study
412 Clear
cell RCC
Array CGH
(2464 BACs)
VHL inactivation,
age, sex, stage, grade
CN loss most frequent at 3p, 14q, 8p, 4q, 9p,
9q, 6q, 3q, 10q, 13q, 1q,
Body mass index,
hypertension,
family cancer Hx,
CN gain at 5q, 7q, 7p, 5p, 20q, 12q, 12p
Stage and grade associated with 1p , 9p ,
9q 13q , 14q , 12qþ
Occupational solvent,
lead, pesticide,
exposures
CNV higher among VHL wild-type compared
to hypermethylated cases
LOH across 3p varied by VHL inactivation status
LINE1 methylation CNV higher in male compared to females
cases, independent of grade, stage
CNV higher in cases without positive family Hx
cancer
Smoking associated with 16p11.2-13.2 gain
Abbreviations: ccRCC, clear cell renal cell carcinoma; CGH, array comparative genomic hybridization; NA, not applicable.
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in earlier studies. Results from reports that employed higher
resolution techniques will complement our study findings and
enable identification of smaller target regions/genes for follow-up.
In summary, we identified novel associations between patient/
clinical characteristics and copy number alterations in a well-
defined ccRCC case-series. Considerable heterogeneity spanning
the FHIT gene locus suggests that this fragile site could be critical
in terms of chromosomal loss of regions distal to 3p14.2 in cases
with VHL promoter hypermethylation. Our findings also suggest
that male tumors may be less genetically stable compared with
those in female cases, and may benefit from more aggressive
follow-up. Lastly, this study provides evidence that loci on 5q may
provide clues to RCC carcinogenesis that could be distinct to the
VHL-HIF pathway.
MATERIALS AND METHODS
Study population
Incident cases (ICD-02 code C.64) were participants in a case–control study
of RCC conducted in seven centers in four Central and Eastern European
countries (Moscow, Russia; Bucharest, Romania; Lodz, Poland; and Prague,
Olomouc, Ceske-Budejovice, and Brno, Czech Republic).14,15 Diagnostic
slides were re-reviewed by an expert renal cancer pathologist for
standardized classification (MM). Of 1097 cases, 763 were ccRCC, and
frozen biopsies were available from 412 (54%) cases. Protocols were
approved by ethics committees and institutional review boards of
participating centers, the International Agency for Research on Cancer
and the US National Cancer Institute. All patients and physicians provided
written informed consent. Patients were asked about lifestyle habits,
height/weight one year before diagnosis, personal/family medical history
and diet.13–16
Array comparative genomic hybridization
Areas of frozen biopsies containing X70% tumor cells were macro-
dissected and non-tumor tissue was removed.13 A standard protocol
(http://cc.ucsf.edu/people/waldman/Protocols) was used to extract DNA.
Arrays included 2464 BACs at approximately Mb intervals along the
genome, printed in triplicate.22,26 DNA samples (500 ng) were labeled as
described previously.27
VHL
Inactivating alterations in exons 1–3 of the VHL gene and promoter
hypermethylation were assessed as described previously.13 Wild-type
tumors included those without sequence alterations affecting the protein
coding region, splice junctions or promoter hypermethylation.
Data processing
Data were processed using SPROC to filter data points with low DAPI
intensity, reference to DAPI signal intensity and correlation between Cy3
and Cy5 within spots. Ratios that were derived from a single clone or those
with a triplicate log2 SD 40.2 were considered missing. Samples were
hybridized on two versions of human array (3.1, 3.2). Clone data were
combined sharing data from both arrays. Post-processing, 2111 clones
remained. Data were mapped to the human DNA sequence May 2004 freeze.
Data were segmented using circular binary segmentation,28
implemented in the DNAcopy package from Bioconductor29 to translate
intensity measurements into equal copy number regions. Median absolute
deviation, scaled by the factor 1.4826 of the difference between the
observed (log2 ratio) and segment values of autosomal clones, were used
to estimate sample-specific experimental variation. Clone status outcome
assignment (gain/loss/normal) was conducted, applying the merge levels
procedure to segment values.30 To identify single technical or biological
outliers (that is, high-level amplifications), their presence was allowed
within each segment. Outlier clones included those for with an observed
value at least four sample-specific median absolute deviation from the
segment. High-level amplifications included narrow and single outliers
with high copy numbers, as described previously.31
To quantify the total amount of genome altered, each clone was
assigned a genomic distance equal to the sum of one half the distance
between its center and that of neighboring clones or to the chromosome
end for probes with one neighbor.31 FGA was defined as the proportion of
the distance of the autosomal clone regions altered to that of the entire
genome. FGG or FGL, considered only distances that were gained or lost.
Clone-wise association tests between copy number alterations and
clinical variables were based on the segment values with observed values
for outlier clones. Moderated t-tests for dichotomous variables and
moderated F-statistics32 were used for more than two groups. P-values
were adjusted for multiple testing by controlling the FDR.32,33 Wilcoxon’s
rank-sum tests were performed to evaluate differential associations of
summary genomic events (that is, FGA, FGG, FGL, amplifications and
specific alterations) with dichotomous variables. Kruskal–Wallis rank-sum
tests were used for events having more than two groups. Statistical
analyses of autosomes were performed using R/Bioconductor.29,34 P-values
o0.05 were considered significant.33
Copy number alterations
The prevalence of ccRCC cases with/without frozen biopsies were
compared by patient characteristics using w2 and Fisher’s Exact tests.
Alterations of chromosome arms were coded as ‘0’ (no alterations) and ‘1’
(dominant change), defined as gain or loss in 425% of cases. Also
included were those previously reported as important alterations in renal
cancer. To compare cases with/without p or q arm alterations, cases with
gains/losses were considered as dependent variables in stepwise logistic
regression models with patient/clinical characteristics, lifestyle and
occupational exposure variables. Criteria for inclusion into multivariate
models was a P-value o0.20. Study design matching variables (country,
sex, age) were included in all models. All variables were fitted in logistic
models to obtain odds ratios (OR) and 95% confidence intervals (95% CI) as
risk estimates of each alteration. Individual clone copy number differences
between groups were initially tested using a moderated t-statistic or
F-statistic with pooled variance, adjusted for multiple comparisons
controlling the FDR.32 Clones identified through the first screen,
observed in 420% of cases, were included in multivariate analyses
conducted using SAS 9.1.3 (SAS Institute Inc.) and STATA 10.0 software.
Clone-wise tests were conducted in R,34 all were two-sided.
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